Have Therapeutics Enhanced Our Knowledge of Axial Spondyloarthritis?

Harrison, S. R.; Marzo‐Ortega, Helena

doi:10.1007/s11926-023-01097-7

Cited by 7 publications

(1 citation statement)

References 128 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…TNFi has been a treatment option, and infliximab, etanercept, adalimumab, golimumab, and certolizumab pegol have been approved for axSpA. Infliximab has been approved exclusively for r-axSpA whereas the others have been approved for nr-axSpA and r-axSpA [ 83 ]. Evidence indicates this class of drugs has substantial benefits over placebo in controlling disease activity, enhancing functionality, and reaching partial remission [ 84 ].…”

Section: Managementmentioning

confidence: 99%

Diagnosis, monitoring, and management of axial spondyloarthritis

Zimba,

Kocyigit,

Korkosz

2024

Rheumatol Int

View full text Add to dashboard Cite

Axial spondyloarthritis (axSpA) is a chronic condition predominantly affecting the spine and sacroiliac joints. This article provides an in-depth overview of the current approaches to diagnosing, monitoring, and managing axSpA, including insights into developing terminology and diagnostic difficulties. A substantial portion of the debate focuses on the challenging diagnostic procedure, noting the difficulty of detecting axSpA early, particularly before the appearance of radiologic structural changes. Despite normal laboratory parameters, more than half of axSpA patients experience symptoms. X-ray and magnetic resonance imaging (MRI) are essential for evaluating structural damage and inflammation. MRI can be beneficial when there is no visible structural damage on X-ray as it can help unravel bone marrow edema (BME) as a sign of ongoing inflammation. The management covers both non-pharmacological and pharmacological approaches. Lifestyle modifications, physical activity, and patient education are essential components of the management. Pharmacological therapy, including nonsteroidal anti-inflammatory drugs (NSAIDs) and biologic disease-modifying anti-rheumatic drugs (bDMARDs), are explored, emphasizing individualized treatment. To effectively manage axSpA, a comprehensive and well-coordinated approach is necessary, emphasizing the significance of a multidisciplinary team. Telehealth applications play a growing role in axSpA management, notably in reducing diagnostic delays and facilitating remote monitoring. In conclusion, this article underlines diagnostic complexities and emphasizes the changing strategy of axSpA treatment. The nuanced understanding offered here is designed to guide clinicians, researchers, and healthcare providers toward a more comprehensive approach to axSpA diagnosis and care.

show abstract

Section: Managementmentioning

confidence: 99%